The selling is routine in both dollar amount and as a fraction of market cap. Director Rhodes' sales are likely part of a pre-arranged 10b5-1 plan or portfolio diversification. No insider buying to suggest bullish conviction. Monitor for any material news (e.g., clinical trial updates) that could explain the selling, but the cluster alone does not warrant a bearish read.
Price Chart
Executive Summary
Two Dyne Therapeutics directors sold a total of ~$1.15M in stock over a 7-day window, with Director Rhodes Jason P executing the bulk of the sales (~$2.6M across multiple trades). The selling represents ~0.04% of the company's $2.9B market cap, which is trivial and routine. No insider buying was reported, and the cluster is dominated by a single director's open-market sales.
Key Financial Metrics
Key Facts
- Total insider sales of ~$1.15M over 7 days, representing ~0.04% of $2.9B market cap
- Director Rhodes Jason P sold 142,924 shares for ~$2.6M across three trades (Apr 24-28)
- Director Kersten Dirk sold 2,700 shares for $53K on Apr 22
- Director Lubner David Charles gifted 53,625 shares (non-cash, $0 value) on Apr 24
- No open-market purchases by any insider in the cluster
- Prior 30-day insider activity shows 9 sells totaling $8.6M, consistent with ongoing selling pattern
Financial Impact
Total insider sales of ~$1.15M, or ~0.04% of market cap — immaterial
Risk Factors
- Continued insider selling pattern (9 sells / $8.6M in prior 30 days) could indicate lack of confidence if it accelerates
- No insider buying to counterbalance the selling signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1777584169350 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access